BIO: Deals, Investment At Risk If IPR Course Unchanged
This article was originally published in Scrip
Executive Summary
If the US Supreme Court permits the process for so-called inter partes reviews (IPRs) to remain on its current course, not only will patent claims held by innovator drug makers likely continue to be invalidated at unprecedented levels, but investment in the biopharmaceutical sector and partnering and acquisition deals among drug companies are at greater risk of falling apart, said Tom DiLenge, general counsel and head of public policy at the Biotechnology Innovation Organization (BIO).
You may also be interested in...
Innovators Employ Labyrinthine Defenses To Fend Off Biosimilars
Innovators are using increasingly complicated tactics in the high-stakes game of keeping biosimilars at bay to ensure their brand-name medicines can keep hauling in the cash for as long as possible.
Innovators Employ Labyrinthine Defenses To Fend Off Biosimilars
Innovators are using increasingly complicated tactics in the high-stakes game of keeping biosimilars at bay to ensure their brand-name medicines can keep hauling in the cash for as long as possible.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.